Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by progressive loss of memory and cognition in the elderly. One of the most important and initial step involves proteolytic cleavage of amyloid precursor protein (APP, chromosome 21) releasing short 40, 42 & 43 aa peptides (beta amyloid1–40, 1–42, and 1–43). Polymerization of b-amyloid (Ab) and subsequent neuronal deposit (amyloid) leads to the degeneration of neurons involved in memory and cognition. Ab deposits have also been found to contain 2 additional proteins termed a-synuclein and b-synuclein. The 140 aa a-synucleins is identical with non-Ab component (NACP) of AD. The 134 aa b-synuclein is homologous to 14kD bovine phosphoneuroprotein 14. Mutations in a-synuclein gene causing a replacement of alanine with a threonine has the potential to cause the protein to misfold. Synucleins are primarily expressed in the brain. At least 3 forms, two large (140 aa SYN-1 & 149 aa SYN-2) and a small form (SYN-3, 42 aa) are produced by alternative splicing.
15 aa peptide located near the C-terminus of human synuclein-beta
Storage and Stability:Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile buffer or ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
仕様
Size：100ug
Source Antigen：Human synthetic peptide
Grade：Purified
Purity：Purified
Form：Supplied as a lyophilized powder from PBS, 0.05% sodium azide.
Specificity：Recognizes human, mouse and rat beta Synuclein. The peptide sequence corresponding to human beta-synuclein (134 aa) is identical in rat beta-synuclein (137 aa) and bovine PNP14 (134 aa). It has no appreciable homology with synuclein-alpha or other proteins.
